Rezolute, Inc. (RZLT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Rezolute, Inc. (RZLT) closed at USD 3.90 on 2026-10-15, a change of -59.1 % over the past year, with a market capitalization of USD 346.27M.

Rezolute, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Rezolute, Inc. key figures

Previous close

USD 3.90 (2026-10-15)

1-year change

-59.1 %

Market cap

USD 346.27M

Enterprise value

USD 239.4M

P/E ratio (trailing)

-4.77

P/E ratio (forward)

-7.69

EPS (trailing)

-0.75

EPS (forward)

-0.47

PEG ratio

n/a

Price to book

3.43

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.13

Employees

58

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Rezolute, Inc.

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Rezolute, Inc. and compare it with other stocks.